Comparison
Cagrilintide vs. Sermorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
1415456-99-3
86168-78-7
Molecular weight
4253.7 g/mol
3358 g/mol
Half-life
168 h
0.2 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYYADAIFTNSYRKVLGQLSARKLLQDIMSRMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Sermorelin
Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
3
3
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
1
3